oral semaglutide 50 mg obesity oasis 1 nejm 2023 oasis 1 oral semaglutide 50 mg nejm 2023 obesity The Rise of Oral Obesity Therapies: Semaglutide and Orforglipron-bsmoothhr oasis 1 oral semaglutide 50

In JAMAs 2025 study, only 35% of initially-rejected prescriptions were resolved on the same day, and the median resolution time was 6 days (interquartile range 312 days) for those requiring multiple-day reviews ( [5] )

doi: 10.1016/j.autrev.2025.103752 69 JiangHZhangXWuYZhangBWeiJLiJet al

Severe symptoms or those that worsen over time require professional evaluation

While elevated MMA blood concentration is considered the specific indicator of deficiency (19), other clinical assays are often used as biomarkers of vitamin B 12 status sometimes in combination

The team is now working on optimizing protocols to be able to test the activity of these compounds